Which company produces neratinib/neratinib (He Li'an)?

Neratinib/Neratinib was originally developed by the American biopharmaceutical company Puma Biotechnology, Inc., which focuses on the research and development of targeted tumor treatment drugs, especially focusing on tumors related to the HER2 signaling pathway. As one of its flagship products, neratinib was first approved by the US FDA in 2017 for the extended adjuvant treatment of HER2-positive early breast cancer. In the following years, it was successively approved for marketing by the European Union and multinational drug regulatory authorities.

In the production process, the original drug of neratinib is manufactured by the German pharmaceutical company Excella GmbH & Co. KG. The company has an internationally leading GMP quality system in small molecule chemical synthesis and complex preparation production. Excella maintains a long-term strategic cooperation with Puma and is responsible for the global drug production and supply of neratinib. Its factory is located in Feucht, Germany, and is famous for its high-purity synthesis technology and stable drug dissolution control, ensuring the consistency of bioavailability of each batch of drugs.

In the Chinese market, neratinib was introduced by authorized partners and completed registration review. It is currently sold as an original imported drug. With the improvement of the global drug supply chain, Excella's production system provides a strong guarantee for the stable supply of neratinib in the international market. At the same time, many domestic pharmaceutical companies are also actively promoting the research and development of generic drugs of neratinib, which is expected to further reduce treatment costs and improve drug accessibility in the future.

The R&D and production process of neratinib reflects the highly collaborative model of the international pharmaceutical industry chain: the United States is responsible for innovative R&D and clinical trials, Europe is responsible for high-quality production and export, and China has become a key market for clinical implementation and popularization of medical insurance. This global collaborative framework accelerates the availability of innovative medicines, allowing patients with HER2-positive breast cancer to access advanced targeted therapies in less time.

Reference materials:https://en.wikipedia.org/wiki/Neratinib